Aire MedTech

Better dosing.
Better medicine.

Where precision matters most, small differences in dose make big differences in outcome. Our assays make sensitive drug measurement possible in any clinical setting, so your drug performs the way it was designed to, in every patient.

Built to fit

No new equipment. No new workflow. No waiting.

Precision dosing that scales to every clinical setting, not just specialist centres.

Built for standard equipment

Our assays are designed to run on analysers already in hospitals. No new instruments to buy, and no new equipment to validate.

Ordered like any other blood test

A drug level is requested the same way as any other blood test and run in the hospital’s own lab. Nothing about the clinical workflow changes.

Results back while it still matters

Sent away to a central facility, a drug level returns days later — often too late to inform the dose it was meant to guide. Run locally, the result arrives while it can still change the decision.

The Science

One platform, built for the drugs that are worth watching

Proprietary assay technology that delivers sensitivity and specificity across the therapeutic range, for a broad range of small molecules.

Our assays are designed for automation. They are homogeneous and mix-and-read. No wash steps, no sample pre-treatment, and no manual handling. The reason our tests can run on the analysers hospital labs already own.

Assays in development include immunosuppressants, kinase inhibitors, antibiotics and small molecule hormones. Analytical performance data available under NDA.

Who we are

Founding team

Tim Luxton, CEO

Bioengineer with his PhD from the University of Leeds, where he developed the assay technology Aire is built on. Now taking it from the lab to the clinic.

Christoph Wälti, Co-founder and Scientific Lead

Professor at the University of Leeds with many years’ experience in biosensors development for clinical diagnostic and translation of healthcare technologies into clinical settings.

Jonathan Sandoe, Co-founder and Clinical Lead

Consultant microbiologist and Associate Professor at the University of Leeds, with over 30 years working in the NHS, Jon’s experience ensures our technology is both useful and useable.

Where it matters

Better dosing, at every stage of a drug’s life

From therapies in use today to assets that never made it.

Drugs already in use

Immunosuppressants like tacrolimus, oncology agents like imatinib, and other narrow-window therapies where dosing decisions are made on limited data. Faster, more sensitive measurement means dose adjustments while they still count.

Drugs in development

A therapy that struggles to show efficacy at a tolerable dose may simply need the right dose in the right patient. With Project Optimus pushing dose optimisation up the oncology agenda, monitoring is becoming part of how drugs get approved.

Assets left behind

Some drugs stall not because the science was wrong, but because dosing them safely wasn’t practical at the time. Reliable measurement can put those assets back in play.

Right dose, right now.

Whether you’re developing a drug or dosing one, we’d like to hear from you

Start a conversation